Lab Services
Forecast Recompete Updated
- Agency
-
Indian Health Service
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $25,000 to $250,000
- Set-aside
- No set-aside
Forecast facts
- Incumbent contract
-
- 75H70925P00140 Federal contract award held by Cepheid Ended Sep 19, 2026 · Value with all options $22,555
- Anticipated award
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Indian Health Service is recompeting a service agreement for GeneXpert diagnostic system maintenance and support, with solicitation release estimated for June 1, 2027, and award targeted for September 1, 2027. The contract covers parts, labor, and travel associated with the GeneXpert analyzer, a molecular diagnostic platform used for infectious disease and clinical testing. Key requirements include capability to service and maintain the diagnostic equipment at the IHS facility.
The estimated award value ranges from $25,000 to $250,000. Performance takes place at the Browning, Montana facility. Contracting Officer DeeAndra Salabye (deeandra.salabye@ihs.gov, +1-406-208-8857) and Andrew Baughn (andrew.baughn@ihs.gov) at the Indian Health Service are the primary points of contact.
The recompeted award is Purchase Order 75H70925P00140, previously awarded to Cepheid on September 12, 2025, as a one-year firm fixed-price service agreement valued at $22,555.00, effective September 20, 2025 through September 19, 2026. The incumbent contract covered GeneXpert maintenance, parts, labor, and travel support. Cepheid, based in Sunnyvale, California, is a molecular diagnostics equipment manufacturer with established federal presence across the Veterans Affairs and Indian Health Service.
Forecast text
Cepheid_Analyzer Servive agreement parts/labor/travel
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast